Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
Study sponsor: aTyr Pharma, Inc. · ATYR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-10-23Actual
Enrollment · participants36Actual
Source updated2023-08-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.